EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data

Laurent Peyrin-Biroulet, Maciej Nazar, Anna Sheahan, Anja Geldhof, Ahlem Azzabi, Filip Baert, Charlotte Mailhat, Hélène Rousseau, Jean-François Rahier, Laurent Beaugerie

Digestive and Liver Disease · 2026

DOI: 10.1016/j.dld.2025.09.026 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Laurent Peyrin-Biroulet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nancy University Hospital, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseHumansFemaleAdultMaleMiddle AgedProspective StudiesEuropeNeoplasmsVenous ThromboembolismYoung AdultOpportunistic InfectionsProduct Surveillance, PostmarketingHospitalization

Stichwörter der Autor:innen

InfectionMalignancyProspectiveVenous thromboembolism

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Nancy University Hospital, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
  • Janssen-Cilag Polska Sp. z o.o., Warsaw, Poland. Electronic address: mnazar1@its.jnj.com.
  • Global Epidemiology, Janssen Research and Development, LLC, Spring House, PA, USA. Electronic address: ASheaha1@ITS.JNJ.com.
  • Medical Affairs, Janssen Biologics B.V., Leiden, Netherlands. Electronic address: ageldho1@its.jnj.com.
  • EMEA Medical Affairs, Johnson & Johnson, Casablanca Finance City, Morocco. Electronic address: aazzabi@ITS.JNJ.com.
  • Department of Gastroenterology, AZ Delta, Rumbeke, Belgium. Electronic address: filip.baert@azdelta.be.

Förderung

  • Johnson & Johnson Innovative Medicine

Zitieren

APA

Peyrin-Biroulet, L., Nazar, M., Sheahan, A., Geldhof, A., Azzabi, A., Baert, F., Mailhat, C., Rousseau, H., Rahier, J. F., & Beaugerie, L. (2026). Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.09.026

Vancouver

Peyrin-Biroulet L, Nazar M, Sheahan A, Geldhof A, Azzabi A, Baert F, et al. Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2025.09.026

BibTeX
@article{PeyrinBiroulet2026,
  author = {Peyrin-Biroulet, Laurent and Nazar, Maciej and Sheahan, Anna and Geldhof, Anja and Azzabi, Ahlem and Baert, Filip and Mailhat, Charlotte and Rousseau, Hélène and Rahier, Jean-François and Beaugerie, Laurent},
  title = {Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2025.09.026}
}
Kostenlos starten →